Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer: Results from the Phase 2 InnovaTV 204/GOG-3023/ENGOT-cx6 Study

Time: 2:10 pm
day: Track B - Day 2 PM


  • Review the high unmet need in cervical cancer and educate on tisotumab vedotin MOA
  • Discuss tisotumab vedotin data in recurrent and/or metastatic cervical cancer (innovaTV 201 + innovaTV 204)
  • Provide an overview of TV clinical development plans